Suppr超能文献

原发性松果体恶性黑色素瘤联合手术切除与放疗的疗效:一项系统评价

The effectiveness of combined resection and radiotherapy for primary pineal malignant melanoma: a systematic review.

作者信息

Zhang Jibo, Wei Zixuan, Chen Jincao

机构信息

Department of Neurosurgery, Zhongnan Hospital of Wuhan University, Wuhan, China.

出版信息

Front Neurol. 2024 Jan 17;14:1344672. doi: 10.3389/fneur.2023.1344672. eCollection 2023.

Abstract

OBJECTIVE

To evaluate the effectiveness of combined resection and radiotherapy (CRAR) for the treatment of primary pineal malignant melanoma (PPMM).

METHODS

Relevant studies were identified through a literature search in PubMed, Embase, and Web of Science from 1899 to September 1, 2023. Then we further screened the literature according to the updated PRISMA 2020 guidelines. The article information, patient information, treatment, and survival rate were analyzed. The primary outcome measures the survival rate of CRAR compared with the overall patients and the patients without treatment. Secondary outcome measures operation methods, radiotherapy methods, and dose.

RESULTS

In total, 28 published articles were recorded. Among them, 35.71% (10/28) articles were on CRAR. The median overall survival, CRAR, and no treatment survival were 65, 88, and 12 weeks, respectively. The median overall survival of CRAR was demonstrably better than that of no treatment ( < 0.0001) and overall survival, even with  = 0.1177. Most of the operations adopted a supracerebellar infratentorial approach, and stereotactic radiation to tumor bed usually ranged between 50 and 60 Gy. Small dose and multiple fractions was the most popular radiotherapy method.

CONCLUSION

Currently, CRAR, compared with other treatments, is more beneficial to prolonging the survival of PPMM patients. However, many more clinical cases are needed to verify it as the best treatment approach.

摘要

目的

评估手术联合放疗(CRAR)治疗原发性松果体恶性黑色素瘤(PPMM)的有效性。

方法

通过检索1899年至2023年9月1日期间PubMed、Embase和Web of Science数据库中的相关研究。然后根据更新后的PRISMA 2020指南进一步筛选文献。分析文章信息、患者信息、治疗方法和生存率。主要观察指标为CRAR与所有患者及未治疗患者的生存率比较。次要观察指标为手术方法、放疗方法和剂量。

结果

共记录28篇已发表文章。其中,35.71%(10/28)的文章涉及CRAR。总体生存、CRAR和未治疗生存的中位时间分别为65周、88周和12周。CRAR的中位总生存期明显优于未治疗组(<0.0001),与总体生存期相比,差异也有统计学意义(=0.1177)。大多数手术采用小脑上幕下入路,对肿瘤床的立体定向放疗剂量通常在50至60 Gy之间。小剂量多次分割是最常用的放疗方法。

结论

目前,与其他治疗方法相比,CRAR更有利于延长PPMM患者的生存期。然而,需要更多的临床病例来验证其作为最佳治疗方法的有效性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0476/10875993/62feb3b1c6cf/fneur-14-1344672-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验